Compare Stocks

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTH Arch Therapeutics	$1.18 +1.7%	$2.06	$0.39 ▼ $18.00	$5.59M	3.52	3,038 shs	6,887 shs
DXR Daxor	$9.75 +0.1%	$8.59	$7.11 ▼ $13.13	$46.22M	-0.46	3,419 shs	8,238 shs
INVO INVO Bioscience	$1.38 -9.2%	$1.03	$0.50 ▼ $10.50	$3.78M	1.45	3.14 million shs	1.26 million shs
SINT Sintx Technologies	$0.04 +4.0%	$0.10	$0.02 ▼ $2.13	$943K	1.46	21.33 million shs	102.87 million shs

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTH Arch Therapeutics	+2.33%	-19.80%	-40.20%	-76.59%	-66.09%
DXR Daxor	+1.35%	+0.93%	+16.09%	-2.11%	+973,999,900.00%
INVO INVO Bioscience	-16.48%	+61.70%	+49.02%	+42.06%	-83.55%
SINT Sintx Technologies	+7.24%	+60.64%	-69.23%	-86.48%	-98.09%

Biden’s $374B Giveaway Into This Sector (Ad)

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARTH Arch Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DXR Daxor	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
INVO INVO Bioscience	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SINT Sintx Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARTH Arch Therapeutics	N/A	N/A	N/A	N/A
DXR Daxor	N/A	N/A	N/A	N/A
INVO INVO Bioscience	N/A	N/A	N/A	N/A
SINT Sintx Technologies	2.00	Hold	N/A	N/A

Current Analyst Ratings

Latest DXR, SINT, INVO, and ARTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
2/5/2024	SINT Sintx Technologies	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARTH Arch Therapeutics	$80K	69.92	N/A	N/A	($2.43) per share	-0.49
DXR Daxor	N/A	N/A	N/A	N/A	N/A	N/A
INVO INVO Bioscience	$3.02M	1.25	N/A	N/A	($1.61) per share	-0.86
SINT Sintx Technologies	$2.63M	0.36	N/A	N/A	$1.65 per share	0.03

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARTH Arch Therapeutics	-$6.98M	N/A	0.00	∞	N/A	-6,809.45%	N/A	-386.74%	5/20/2024 (Estimated)
DXR Daxor	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
INVO INVO Bioscience	-$10.89M	-$12.36	N/A	∞	N/A	-459.42%	N/A	-88.87%	5/20/2024 (Estimated)
SINT Sintx Technologies	-$8.26M	-$3.42	N/A	∞	N/A	-314.39%	-67.12%	-45.49%	5/20/2024 (Estimated)

Latest DXR, SINT, INVO, and ARTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/27/2024	Q4 2023	SINT Sintx Technologies	N/A	-$0.09	-$0.09	-$0.09	N/A	$0.90 million
2/20/2024	Q1 2024	ARTH Arch Therapeutics	N/A	-$0.57	-$0.57	-$0.57	N/A	$0.05 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARTH Arch Therapeutics	N/A	N/A	N/A	N/A	N/A
DXR Daxor	N/A	N/A	N/A	N/A	N/A
INVO INVO Bioscience	N/A	N/A	N/A	N/A	N/A
SINT Sintx Technologies	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARTH Arch Therapeutics	N/A	0.16	0.04
DXR Daxor	N/A	N/A	N/A
INVO INVO Bioscience	2.94	0.37	0.31
SINT Sintx Technologies	N/A	1.90	1.60

Ownership

Institutional Ownership

Company	Institutional Ownership
ARTH Arch Therapeutics	6.91%
DXR Daxor	1.34%
INVO INVO Bioscience	12.02%
SINT Sintx Technologies	18.38%

Insider Ownership

Company	Insider Ownership
ARTH Arch Therapeutics	4.50%
DXR Daxor	60.60%
INVO INVO Bioscience	3.50%
SINT Sintx Technologies	1.00%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ARTH Arch Therapeutics	8	4.74 million	4.53 million	Not Optionable
DXR Daxor	N/A	4.74 million	1.87 million	Not Optionable
INVO INVO Bioscience	15	2.74 million	2.39 million	No Data
SINT Sintx Technologies	41	22.68 million	22.45 million	Not Optionable

DXR, SINT, INVO, and ARTH Headlines

Source	Headline
	Why SINTX Technologies Stock Is Getting Hammered msn.com - April 3 at 2:48 PM
	SINTX Technologies Announces Pricing of $1.5 Million Public Offering of Common Stock globenewswire.com - April 3 at 9:00 AM
	Why SINTX Technologies Stock Hit A New All-Time Low Today msn.com - April 1 at 3:51 PM
	DDC Appoints Vice President to Drive Operational Excellence itnewsonline.com - March 30 at 6:23 PM
	SINTX Technologies Announces Proposed Public Offering of Common Stock globenewswire.com - March 29 at 4:00 PM
	SINT Stock Earnings: SINTX Technologies Beats EPS, Beats Revenue for Q4 2023 investorplace.com - March 28 at 7:02 AM
	Sintx Technologies Prices Public Offering Of $1.3 Mln Of Shares markets.businessinsider.com - March 25 at 1:22 PM
	Why SINTX Technologies Stock Is Down 50% msn.com - March 25 at 1:22 PM
	Why Is Sintx Technologies (SINT) Stock Down 31% Today? investorplace.com - March 25 at 9:05 AM
	SINTX Technologies Announces Pricing of $1.3 Million Public Offering of Common Stock globenewswire.com - March 25 at 9:00 AM
	US Stocks Edge Lower; FedEx Posts Upbeat Earnings msn.com - March 23 at 3:15 AM
	Why SINTX Technologies Is Trading Higher Today aol.com - March 22 at 10:14 PM
	Gold Moves Lower; Lululemon Shares Plummet msn.com - March 22 at 5:14 PM
	Dow Dips 200 Points; Nike Shares Fall After Q3 Results markets.businessinsider.com - March 22 at 5:14 PM
	SINTX Technologies Announces Intend To Offer And Sell Shares Of Common Stock; Stock Down 34% markets.businessinsider.com - March 22 at 5:14 PM
	Why SINTX Technologies Stock Is Nosediving msn.com - March 22 at 5:14 PM
	SINTX Technologies Announces Proposed Public Offering of Common Stock globenewswire.com - March 22 at 8:30 AM
	Sintx Technologies (SINT) Price Target Increased by 42.86% to 10.20 msn.com - February 24 at 2:14 PM
	Top 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI) benzinga.com - February 23 at 7:50 AM
	SINTX TECHNOLOGIES ENTERS INTO A SECOND LONG TERM SUPPLY AGREEMENT FOR THE AEROSPACE MARKET finance.yahoo.com - February 21 at 3:58 PM
	SINTX TECHNOLOGIES ENTERS INTO A SECOND LONG TERM SUPPLY AGREEMENT FOR THE AEROSPACE MARKET globenewswire.com - February 21 at 9:00 AM
	SINTX Technologies: Other Events cbonds.com - February 16 at 10:37 AM
	SINTX Technologies subsidiary enters R&D agreement with the U.S. Army DEVCOM ARL for ceramic additive manufacturing tctmagazine.com - February 7 at 10:57 AM
	Sintx Technologies just downgraded at Maxim, here's why realmoney.thestreet.com - February 5 at 5:59 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Arch Therapeutics

OTCMKTS:ARTH

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.

Daxor

NASDAQ:DXR

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.

INVO Bioscience

NASDAQ:INVO

INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. INVO Bioscience, Inc. was founded in 2007 and is based in Sarasota, Florida.

Sintx Technologies

NASDAQ:SINT

Sintx Technologies, Inc., an advanced materials company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, industrial, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial